Table 5. Expression of ApoA-1, ApoC-III, and ApoE Are Correlated with SCLC Sub-Stages.
| Stage | ApoA-1 | ApoC-III | ApoE | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Negative (n/%) | Positive (n/%) | Negative (n/%) | Positive (n/%) | Negative (n/%) | Positive (n/%) | |||||||
| - | + | ++ | +++ | - | + | ++ | +++ | - | + | ++ | +++ | |
| I A (5) | 0% (0/5) | 40% (2/5)* | 60% (3/5) | 0% (0/5)* | 60% (3/5) | 20% (1/5)* | 20% (1/5)* | 0% (0/5)* | 20% (1/5) | 40% (2/5) | 40% (2/5)* | 0% (0/5)* |
| I B (7) | 14.3% (1/7) | 0% (0/7) | 71.4% (5/7) | 14.3% (1/7) | 42.9% (3/7) | 42.9% (3/7) | 0% (0/7) | 14.3% (1/7) | 28.6% (2/7) | 42.9% (3/7) | 14.3% (1/7) | 14.3% (1/7) |
| II A (14) | 14.3% (2/14) | 21.4% (3/14) | 42.9% (6/14) | 21.4% (3/14)* | 35.7% (5/14) | 35.7% (5/14) | 21.4% (3/14)* | 7.1% (1/14)* | 50% (7/14) | 21.4% (3/14)* | 14.3% (2/14)* | 14.3% (2/14)* |
| II B (5) | 0% (0/5) | 20% (1/5) | 40% (2/5) | 40% (2/5) | 20% (1/5) | 40% (2/5) | 40% (2/5) | 0% (0/5) | 0% (0/5) | 40% (2/5) | 40% (2/5) | 20% (1/5) |
| III A (29) | 10.3% (3/29) | 20.7% (6/29) | 51.7% (15/29) | 17.2% (5/29) | 48.3% (14/29) | 27.6% (8/29) | 20.7% (6/29) | 3.4% (1/29) | 17.2% (5/29) | 27.6% (8/29) | 41.4% (12/29) | 13.8% (4/29) |
| III B (23) | 0% (0/23) | 21.7% (5/23) | 47.8% (11/23) | 30.4% (7/23) | 47.8% (11/23) | 43.5% (10/23) | 4.3% (1/23) | 4.3% (1/23) | 17.4% (4/23) | 17.4% (4/23) | 43.5% (10/23) | 21.7% (5/23) |
| IV (4) | 0% (0/6) | 25% (1/4) | 75% (3/4) | 0% (0/4) | 0% (0/4) | 50% (2/4) | 50% (2/4) | 0% (0/4) | 25% (1/4) | 0% (0/4) | 75% (3/4) | 0% (0/4) |
SCLC, small cell lung cancer.
-, <25%; +, 25–50%; ++, 50–75%; +++, >75%.
*p<0.05 (comparison between I A and I B, II A and II B).